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Risk of schizophrenia is conferred by alleles occurring across the full spectrum of
frequencies from common SNPs of weak effect through to ultra rare alleles, some of
which may be moderately to highly penetrant. Previous studies have suggested that
some of the risk of schizophrenia is attributable to uncommon alleles represented on
Illumina exome arrays. Here, we present the largest study of exomic variation in
schizophrenia to date, using samples from the United Kingdom and Sweden (10,011
schizophrenia cases and 13,791 controls). Single variants, genes, and gene sets were
analyzed for association with schizophrenia. No single variant or gene reached
genome-wide significance. Among candidate gene sets, we found significant
enrichment for rare alleles (minor allele frequency [MAF] < 0.001) in genes intolerant
of loss-of-function (LoF) variation and in genes whose messenger RNAs bind to
fragile X mental retardation protein (FMRP). We further delineate the genetic
architecture of schizophrenia by excluding a role for uncommon exomic variants
*These authors contributed equally to this work.
†Co-led the project.
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(0.01 ≤MAF ≥ 0.001) that confer a relatively large effect (odds ratio [OR] > 4). We
also show risk alleles within this frequency range exist, but confer smaller effects and
should be identified by larger studies.
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1 | INTRODUCTION
Schizophrenia is a highly heritable disorder with an average lifetime
risk of 0.5–1%, although this can vary across and within countries
(Gottesman & Shields, 1967). Prior studies point to a multifactorial
aetiology involving genetic and environmental factors and an overall
heritability of around 65% (Cardno & Gottesman, 2000; Lichtenstein
et al., 2009; Sullivan, Kendler, & Neale, 2003). Genomic studies have
decisively supported work from the pre-molecular era suggesting that
schizophrenia is highly polygenic and it is now clear that the large
number of risk alleles involved span the full spectrum of frequencies
from common through rare including de novo mutations (Purcell et al.,
2009). The evidence to date from copy number variants (CNVs)
supports the hypothesis that alleles that confer high risk of
schizophrenia are subjected to strong selection pressure, but are
maintained in the population at low frequencies by de novo mutation
(Rees, Moskvina, Owen, O’Donovan, & Kirov, 2011) and incomplete
penetrance. At the other end of the effect size spectrum, alleles
conferring small effects on risk can become common.
Published genome-wide association studies (GWAS) have
identified over 100 genetic loci containing common alleles (The
Psychiatric Genomics Consortium, 2014). Individually, common risk
alleles contribute small effects (odds ratios typically <1.1) but en
masse, it has been estimated half to a third of the genetic risk of
schizophrenia is indexed by common alleles genotyped by current
genome-wide association study (GWAS) arrays (The Psychiatric
Genomics Consortium, 2014). Rare risk alleles in the form of CNVs
have also been identified; these typically confer relatively high risk of
disorder (odds ratios 2–60) and in total occur in about 3% of cases as
inherited or de novo mutations (Giusti-Rodríguez & Sullivan, 2013).
Whole-exome sequencing studies support a polygenic contribution
to the disorder from both inherited and de novo rare single
nucleotide variants (SNVs) and insertion/deletion variants (Fromer
et al., 2014; Genovese et al., 2016; Purcell et al., 2014). Studies
documenting a burden of rare nonsynonymous SNVs in people with
the disorder suggest that, as for GWAS and CNV analyses, the
application of large samples will ultimately deliver significant findings
for this class of risk variant (Zuk et al., 2014). Recent support for this
comes from a recent meta-analysis of 4,264 schizophrenia cases,
9,343 controls, and 1,077 parent-proband trios in which genome-
wide significant support was obtained for rare loss-of-function SNVs
in the gene SETD1A (Singh et al., 2016).
We have previously shown that alleles represented on exome
arrays capture a fraction of the risk for schizophrenia attributable to
rare SNVs (Richards et al., 2016) but, as with sequencing studies, our
study was underpowered to implicate specific genes. To enhance
power, we have increased the sample size to 10,011 schizophrenia
cases and 13,791 controls by combining two of the largest
schizophrenia case-control cohorts available from theUnited Kingdom
(5,585 cases and 8,103 controls) and Sweden (4,426 cases and 5,688
controls). The analysis of the UK sample exome chip data has
previously been published (Richards et al., 2016), as has the Sweden
whole exome sequencing results (though not the Sweden exome chip
data) (Genovese et al., 2016).
We performed three primary analyses. These were single variant
association using mixed model analysis, gene association using
SKAT-O, and gene set analysis using a burden test in SKAT. The
candidate gene sets were chosen on the basis of available evidence
from other types of genetic study of neuropsychiatric disorders (for
more details see section 2.4).We hypothesized that, as the rarity of the
variants and the large multiple testing correction was likely to lead to
limited power to detect true associations for single variants (see
section 2.5), the candidate gene sets with good prior evidence had the
best chance of capturing a true association with schizophrenia.
2 | METHODS AND MATERIALS
2.1 | Samples
Sample sizes are given in Supplementary Table S1. The UK
schizophrenia cases were from the CLOZUK and Cardiff COGS
cohorts, both described previously and that are typical of schizophre-
nia with respect to the heritability conferred by common alleles
(Hamshere et al., 2013). CLOZUK cases were prescribed the
antipsychotic clozapine. This is primarily used for treatment-resistant
schizophrenia, so the CLOZUK cases are likely to be enriched for
treatment resistance. In the United Kingdom, patients taking clozapine
provide blood samples to allow the detection of adverse drug-effects.
Following ethical approval, we obtained anonymous blood samples
(Hamshere et al., 2013). Cardiff COGS cases were recruited from
community mental health teams inWales and England on the basis of a
clinical diagnosis of schizophrenia or schizo-affective disorder
(depressed sub-type) as described previously (Carroll et al., 2011).
After written informed consent, diagnosis was subsequently
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established using the Schedules for Clinical Assessment in Neuropsy-
chiatry (SCAN) instrument (Wing et al., 1990) and review of case notes
followed by consensus diagnosis according to DSM-IV (American
Psychiatric Association, 1994) criteria. Controls were taken from the
UK Blood Service donors (4,455 samples) and the 1958 British Birth
Cohort (4,615 samples) (Power & Elliott, 2006; Power et al., 2007;
WTCCC, 2007). The study had UK Multicenter Research Ethics
Committee approval.
Swedish cases with schizophrenia were identified via the Swedish
Hospital Discharge Register which captures all public and private
inpatient hospitalizations (Genovese et al., 2016; Ripke et al., 2013;
Szatkiewicz et al., 2014). Cases were required to have two or more
inpatient admissions for schizophrenia or schizo-affective disorder.
The validity of this case definition of schizophrenia is strongly
supported (Dalman, Broms, Cullberg, & Allebeck, 2002; Kristjansson,
Allebeck, & Börje, 1987). All procedures were approved by ethical
committees at the Karolinska Institute in Sweden, and all subjects
provided written informed consent (or legal guardian consent and
subject assent). Controls were selected at random from Swedish
population registers, and had never been hospitalized for schizophre-
nia, schizo-affective disorder, or bipolar disorder.
For replication of rs61749465, we obtained data from an
additional UK (UCL) schizophrenia cohort of 1,305 subjects who had
received a clinical diagnosis of schizophrenia according to ICD-10
which was subsequently confirmed by interviews using the
Schedule for Affective Disorders and Schizophrenia—Lifetime edition
(SADS-L) (Endicott & Spitzer, 1978). The UCL control cohort included
1,309 subjects (480 were unscreened healthy UK subjects from the
European Collection of Animal Cell Culture). The remaining UCL
controls had no personal history of any RDC-defined mental disorder
and no family history of schizophrenia, alcohol dependence, or bipolar
disorder. All cases and controls were of United Kingdom or Irish
ancestry as described previously (Datta et al., 2010). UK National
Health Service multicenter and local research ethics approvals were
obtained and signed informed consent was given by all subjects.
Genotyping of the primary datasets was performed using Illumina
HumanExome or HumanOmniExpressExome arrays (see URLs below).
Whole exome sequencing of ∼10% of the Sweden cohort was used in
array design. We restricted our analyses to the exome content
contained in both arrays (N = 247,870 SNVs). Genotypes were called
using Illumina GenomeStudio with subsequent processing of genotype
with zCall (Goldstein et al., 2012) with batch-specific intensity data.
Cardiff COGS, CLOZUK, UK Blood Service donors, and the Swedish
cohort were genotyped at the Broad Institute (Cambridge, MA). The
1958 British Birth Cohort was genotyped by the Wellcome Trust
Sanger Institute.
Replication data for rs61749465 was genotyped in the UCL
sample using a KASPar assay (LGC Genomics, Hoddesdon, UK) and
heterozygotes confirmed by Sanger sequencing.
Quality Control (QC) was performed following the procedures we
previously described (Richards et al., 2016). In brief, marker QC
consisted of exclusions based on call rate <99%, Hardy–Weinberg
Equilibrium (HWE) p < 1 × 10−6 in cases and controls separately,
p < 5 × 10−4 in case/case batch comparisons, p < 1 × 10−3 in control/
control batch comparisons and passing cluster plot separation checks
(markers with GenTrain score < 0.4 or mean cluster separation < 0.08
were excluded). QC steps for subject exclusionswere based on call rate
<98%, relatedness based on identity by descent π^ < 0.1, heterozygos-
ity, and PCA for population stratification. Of 6,991 cases and 9,070
controls initially available for the UK cohorts, 5,585 cases and 8,103
controls were retained. Principal component analysis (PCA) was used
to control for population stratification. As in the previous analysis,
CLOZUK/COGS PCA was performed using SmartPCA 3.0 on 5,128
variants with MAF > 0.01 and 1,100 samples from 11 populations
using HapMap 3 (Thorisson, Smith, Krishnan, & Stein, 2005) as
reference panel (Patterson, Price, & Reich, 2006; Price et al., 2006).
QC details for the Swedish cohort (4,610 cases and 5,894 controls
before QC) are given in Supplementary Table S2. Marker QC consisted
of exclusions based on call rate < 98% and HWE p < 1 × 10−6 in cases
and controls separately. QC steps for subject exclusionswere based on
call rate <98%, relatedness based on identity by descent π^ < 0.1,
heterozygosity, and PCA for population stratification. In the Swedish
cohort, PCA was performed with SmartPCA v3.0 (Price et al., 2006)
using LD pruned genome-wide SNPs (these data were not available for
all UK controls). Samples that were >6 standard deviations from the
mean on PCA1 to PCA10 were dropped, and the process iterated 10
times. After QC, we retained 4,426 cases and 5,688 controls in the
Swedish cohort. PLINK1.9 was used to perform all QC steps except for
PCA (Purcell et al., 2007).
In total, there were 10,011 cases and 13,791 controls in the
combined sample.
2.2 | Allelic association
Allelic association testingwas performed in GCTA (Yang, Lee, Goddard,
& Visscher, 2011), using mixed linear model based association analysis
(MLMA) based on the leave-one-chromosome-out method (MLMA-
loco) (Yang, Zaitlen, Goddard, Visscher, & Price, 2014). This method
provides controls for population stratification and sample relatedness.
We concentrate on 112,950 variants withMAF < 0.01 (Supplementary
Table S3).
2.3 | Gene-level association
We implemented tests to summarize the evidence for gene-level
association based on all nonsynonymous variants (MAF < 0.001,
92,815 variants) in a gene. This MAF threshold was chosen because
it captured the greatest proportion of the rare variant signal in a
exome-sequencing study of schizophrenia (Fromer et al., 2014). We
used SeqMeta 1.6.5 (URLs) available in R for meta-analysis of the
United Kingdom and Swedish cohorts to calculate unified Sequencing
Kernel Association (SKAT-O) tests and burden tests for genes. The
burden test collapses minor alleles within a gene or pathway into a
single variable (Li and Leal, 2008;Madsen &Browning, 2009) and is the
most powerful approach when most of the minor alleles in the gene of
pathway increase risk. SKAT aggregates genetic information by using
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multiple logistic regression in a kernel framework and is more powerful
than the burden test when minor alleles show a mixture of risk or
protective effects (Wu et al., 2011). The unified test (SKAT-O)
maximizes power by finding the optimal linear combination of the
burden and SKAT approaches (Lee et al., 2012).
We annotated variants with MAF < 0.001 to genes according to
the RefSeq hg19 (URLs). For gene-wide association tests, we included
only genes containing ≥2 variant sites in the datasets (13,443 genes;
Supplementary Table S4). For both cohorts, we included 11 covariates
(10 ancestry principal components and a covariate for genotyping
platform).
2.4 | Gene-set analyses
Gene-sets were selected given a priori evidence of enrichment for rare
alleles. We thus conducted only the burden test using the SeqMeta
package in R. As schizophrenia is highly polygenic, gene-sets analyses
are at their most informative when they are competitive against the
genomic background (de Leeuw, Neale, Heskes, & Posthuma, 2016) so
we included a covariate corresponding to the rare allele count for each
individual for variants outside the candidate pathways.
We defined candidate gene sets based on previous evidence
of enrichment for rare alleles from sequencing studies of
schizophrenia (Tables 3 and S5; Supplementary Material for
more information on how these pathways are derived) (Akawi
et al., 2015; Bragin et al., 2014; Chen & Dent, 2014; Chiurazzi,
Schwartz, Gecz, & Neri, 2008; de Ligt et al., 2012; De Rubeis et al.,
2014; Lek et al., 2015; Fromer et al., 2014; Giusti-Rodríguez &
Sullivan, 2013; Khare et al., 2012; Network and Pathway Analysis
Subgroup of Psychiatric Genomics Consortium, 2015; Najmabadi
et al., 2011; Purcell et al., 2014; Rauch et al., 2012; Singh et al.,
2016; The Psychiatric Genomics Consortium, 2014; van Bokhoven,
2011; Yun, Wu, Workman, & Li, 2011). For generic pathway
exploration, we extracted 8,737 pathways from six publically
available repositories (Supplementary Tables S6 and S7 and
Supplementary Material) (Ashburner et al., 2000; Croft et al.,
2014; Eppig et al., 2015; Gene Ontology Consortium, 2015;
Kanehisa & Goto, 2000; Kanehisa et al., 2014; Mi, Muruganujan,
Casagrande, & Thomas, 2013; Mi, Muruganujan, & Thomas, 2013;
Milacic et al., 2012; Schaefer et al., 2009). We performed gene-set
analyses based on the full set of exonic variants (Supplementary
Table S6), and another set of analyses restricted to damaging
mutations (those annotated as “stop” or “splice”; Supplementary
Table S7).
2.5 | Statistical power
Given our sample sizes, we had 95% power to detect association to an
allele with a MAF of 0.001 and odds ratio >4 at an exome-wide
significance threshold (p < 1.2 × 10−7, as suggested for moderate
impact nonsynonymous variants; Sveinbjornsson et al., 2016).
Statistical power was <1% to detect alleles at this frequency with an
OR of 2 (Figure 1).
3 | RESULTS
3.1 | Allelic association
No single variants reached the exome-wide significance threshold
(p < 1.2 × 10−7). One variant, rs61749465 (exm679123, in MCPH1),
neared this level of significance (p = 3.8 × 10−7). However, we did not
obtain replication evidence for rs61749465 (Fisher’s exact test
p = 0.12) for this allele in the sample from UCL (1,305 cases and
1,309 controls), nor did meta-analysis of rs61749465 in the UCL
sample with the UK and Swedish cohorts provide additional support
(Fisher’s combined probability test; p = 8.2 × 10−7). The results for
variantswith p < 1 × 10−4 are presented in Table 1 and results for all the
variants in Supplementary Table S3. Overall, 12 variants showed
evidence for association below 10−4, similar to the number expected
under the null.
3.2 | Gene association tests
None of the gene association results exceeded the gene-wide
significance threshold for SKAT-O or burden tests (p < 2.5 × 10−6,
Bonferroni correction for 20,000 genes). Genes significant at
p < 3 × 10−3 are given in Table 2. The complete list of gene level
results is given in Supplementary Table S4.
3.3 | Pathway analyses
For the candidate gene set analysis using a burden test on rare
variants (Table 3), two gene sets, FMRP targets (Fromer et al., 2014;
Giusti-Rodríguez & Sullivan, 2013) and those that are loss-of-
function intolerant (defined as those with pLin ≥ 0.9 (Lek et al., 2015;
Genovese et al., 2016), were significantly enriched, each passing the
Bonferroni threshold for this analysis of p < 4.1 × 10−3. Our
FIGURE 1 Power calculations for SNVs under an additive allelic
model. Power calculations assume a variant with MAF = 0.001
(green line) or 0.01 (blue line) and a sample size of 10,011 cases and
13,791 controls. Significance is set at α = 1.2 × 10−7. Similar results
are obtained for a dominant model given the low MAF
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exploratory analysis of public repositories of gene-set annotations
identified no additional gene set that passed the Bonferroni
significant threshold level of 5.7 × 10−6 (for the 8,737 pathways)
when all we tested all mutations or only those predicted to be loss-
of-function (Supplementary Tables S6 and S7).
4 | DISCUSSION
Exome sequencing and CNV studies have demonstrated that very rare
variants that confer substantial effects on risk make a contribution to
the genetic architecture of schizophrenia. Postulating that a propor-
tion of this architecture could be captured at low cost using Illumina
exome arrays containing by uncommon genetic variation, we have
conducted the largest rare-variant study of schizophrenia to date.
We found no evidence supporting association to any variant
present on Illumina exome arrays. Our high power to detect
uncommon alleles (0.01 ≤MAF ≥ 0.001) that confer a large effect
(OR > 4) effectively excludes the possibility that such alleles are
present on these arrays (Figure 1). The Sweden sample should have
been particularly tractable to this approach given that exon variation
from Sweden informed Illumina exome array design. These findings
also constrain expectations of what might be delivered by larger
studies based on these arrays. Our study does not, however, exclude
the possibility that some of the alleles within this frequency range
confer weaker effects on risk; indeed the gene-set analyses (see
section 3.3 and discussion below) imply that at least some do.
SKAT-O and burden analyses designed to enhance power in
the event of allelic heterogeneity also failed to implicate any single
TABLE 1 SNV association tests
Variant Chr Position A1 A2 MAF (cases) MAF (controls) Odds ratio p Gene
exm679123 8 6272353 G A 0.00460 0.00199 1.196 3.78E-07 MCPH1
exm237695 2 166003301 T C 0.00180 0.00054 1.300 9.55E-06 SCN3A
exm1212971 16 4253250 T C 0.00055 0.00004 1.683 1.23E-05 SRL
exm1511038 19 56539847 A G 0.00055 0.00000 1.747 1.72E-05 NLRP5
exm1217358 16 11001377 C G 0.00000 0.00058 0.646 3.12E-05 CIITA
exm750535 9 36147794 G A 0.00090 0.00018 1.433 3.91E-05 GLIPR2
exm843062 10 95400694 A C 0.00574 0.00845 0.911 5.13E-05 PDE6C
exm1330168 17 43308023 G A 0.00015 0.00098 0.730 7.13E-05 FMNL1
exm491315 5 142593652 C T 0.00674 0.00906 0.917 7.40E-05 ARHGAP26
exm1055306 13 20224268 G T 0.00020 0.00094 0.743 7.67E-05 MPHOSPH8
exm252299 2 189932953 A G 0.00140 0.00065 1.278 8.85E-05 COL5A2
exm888875 11 8478972 G C 0.00045 0.00152 0.761 9.42E-05 STK33
SNV association test results, limited to p < 1 × 10−4 and MAF < 0.01. Variant column denotes Exome chip probe ID. “Chr” column gives chromosome.
Chromosome and position are according to human genome build 37. A1 and A2 are the alleles for each variant. Odds ratio is for the A1 allele.
TABLE 2 Gene-wise tests
Gene Chr Gene start Gene end SKAT-O p Burden test p Odds ratio (burden) N SNVs
POLR1E 9 37485931 37503694 9.80E-05 9.88E-05 3.118 4
CEP192 18 12991360 13125051 9.91E-05 6.02E-01 1.066 23
ARHGEF28 5 72921982 73237818 1.38E-04 8.36E-05 1.634 21
DNAH11 7 21582832 21941186 1.82E-04 9.87E-05 1.369 66
FOCAD 9 20658307 20995954 2.58E-04 2.70E-01 1.193 24
CSDE1 1 115259533 115300671 2.98E-04 5.13E-01 0.836 8
WDR89 14 64063756 64108641 4.19E-04 4.38E-04 3.255 2
MYCL 1 40361095 40367687 5.31E-04 4.93E-02 0.538 3
MRGPRF 11 68771861 68780850 5.87E-04 4.89E-04 3.768 5
SETX 9 135136826 135230372 6.13E-04 8.35E-02 1.284 23
ZNF610 19 52839497 52870376 8.13E-04 1.23E-01 1.516 6
SKAT-O and burden tests results (p < 0.001) for SNVswithMAF < 0.001. “Chr” column gives chromosome. Positions are for human genomebuild 37. SKAT-O
p denotes SKAT-O gene association p-value. Burden test p is the burden test gene association p-value. Odds ratios are given for the burden tests. N SNVs is
number of variants tested.
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gene for schizophrenia. Two results here are notable. First, the
association evidence for WDR88 (p = 0.003) which we previously
reported to be associated with schizophrenia (Richards et al., 2016),
was considerably diminished by addition of the Swedish data,
suggesting the previous report is likely to be a false positive. We
similarly found no support for SETD1A (Supplementary Table S4)
which was recently found to be significantly enriched for ultra-rare
loss-of-function mutations in people with schizophrenia (Singh et al.,
2016). However, given that the association evidence in that study
derived from extremely rare events and de novo loss-of-function
mutations, none of which is represented on these Illumina exome
arrays, our study should not be viewed as inconsistent with the
earlier study.
Although we found no significant association signals for
individual alleles or genes, we did find evidence that uncommon
nonsynonymous mutations were weakly enriched in two gene sets,
predicted targets of FMRP and genes that are intolerant of loss-of-
function mutations. FMRP targets have been shown to be enriched
in schizophrenia for exonic mutations (both de novo [Fromer et al.,
2014] and segregating [Purcell et al., 2014]) while LoF
intolerant genes have been shown to be enriched for rare exonic
mutations in a large sequencing study of the disorder (Genovese
et al., 2016). Both gene-sets were also significantly enriched for
common variation in the largest GWAS of schizophrenia (Pardiñas,
2016). Our findings in FMRP and LoF-intolerant gene-sets are,
therefore, consistent with studies using a range of designs.
The consistency of findings across markedly different types of
genetic variation and in widely varying study designs is
remarkable. It also provides a compelling body of evidence that
identifying the causal genetic variation within these gene sets has
the potential to provide true insights into the primary aetiology of
schizophrenia.
The magnitude of the enrichments of these gene-sets for
mutations in the present study is much smaller (Table 3;
ORs ≤ 1.023) than that reported in the most recent exome
sequencing study (OR ≈ 1.2) (Genovese et al., 2016) but the latter
was based on ultra-rare variants (i.e., occurring once in the sample
and not present in a large exome database; Lek et al., 2015). This
class of mutation is expected to be more highly enriched for
damaging mutations than those represented on exome arrays.
Restricting our analyses to variants on the arrays that are predicted
to be loss-of-function did not enhance the signal in these pathways
(Table 3). The differences in the variant frequency profiles between
arrays and sequencing may also explain the absence of signals in
other gene sets that have been consistently implicated in the
disorder through CNV and exome sequencing, particularly the
smaller gene sets such as ARC and NMDAR (Fromer et al., 2014;
Purcell et al., 2014).
In conclusion, in the largest exome study of schizophrenia to
date, we fail to implicate individual risk alleles or risk genes. We
confirm enrichments in two gene-sets that have previously been
strongly implicated in the disorder. The associations in these
pathways arise from exonic variation that is rare (MAF < 0.001)
but not ultra-rare or uniquely present in a single person. Associations
to individual alleles or genes within this pathway should be
achievable using this technology, although the sample sizes required
will have to be larger than those that brought the early successes in
GWAS of the disorder.


















ASD de novo nonsynonymous 0.075 1.007 0.004 24,153 2,698 0.934 1,680 0.999
ASD de novo loss of function 0.637 0.991 0.019 1,379 960 0.602 1,372 0.990
ARC/NMDAR 0.740 0.987 0.040 296 58 0.383 23 1.141
Calcium channels 0.980 0.999 0.047 194 28 0.143 17 0.673
Developmental delay 0.048 1.013 0.006 10,013 1,284 0.635 719 0.986
FMRP targets 0.003 1.023 0.008 7,022 810 0.978 351 0.999
Histones 0.070 1.034 0.019 1,201 188 0.585 73 0.956
Loss of function intolerant 0.003 1.014 0.005 16,831 2,808 0.213 829 0.969
PGC2 SZ genome-wide
significant
0.166 1.023 0.016 1,614 295 0.034 110 1.165
Post synaptic density (PSD) 0.671 0.995 0.011 3,389 602 0.602 198 1.027
Schizophrenia de novo
nonsynonymous
0.633 1.003 0.007 8,661 922 0.741 561 0.990
Schizophrenia de novo loss of
function
0.362 0.970 0.034 458 335 0.343 457 0.969
The results of burden test (Burden p) analyses of candidate gene sets limited to SNVswithMAF < 0.001. Tests involving all nonsynonymous variants or those
that are loss of function are in columns labeled, respectively, all and LoF. N SNVs is the number of variants in pathway that pass quality control with
MAF < 0.001.N genes (all) is number of genes in the pathway that contain at least one nonsynonymous variant. Burden p is for the burden test of association
based on minor alleles.
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URLS
Exome SNP genotyping selection: http://genome.sph.umich.edu/
wiki/Exome_Chip_Design. SeqMeta, https://github.com/DavisBrian/
seqMeta. Gene list for hg19: https://www.cog-genomics.org/plink2/
resources#genelist
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